RetinAI and Gutblick, a Swiss clinical network, are partnering to use RetinAI's Discovery platform for two projects focused on research and clinical application for patients with Dry Age-related Macular Degeneration. This collaboration aims to enhance personalized treatment, support target-based patient selection and establish a clinical center of excellence.
RetinAI develops software solutions for experts in ophthalmology to accelerate clinical, research and pharmaceutical workflows globally using advanced machine learning and computer vision. Its FDA-cleared and CE-marked data management platform, RetinAI Discovery, analyses datasets at scale to gain a deep understanding of biomarker profiles and patient subgroups or outcomes.
The platform will build the core of the newly initiated research project featuring RetinAI and the Gutblick, a leading group of ophthalmology centers in Switzerland dedicated to excellence in eye care. The pilot project aims to address a range of questions and develop new algorithms focused on Intermediate AMD (iAMD) applications and identifying and monitoring biomarkers for the progression to Geographic Atrophy (GA). The pilot phase aims to provide critical insights into the workflow at Gutblick with the potential expansion into general medical retina clinics and other Gutblick sites.
The Discovery® platform will be used to perform large-scale analysis of Real-World Data, aggregating patient data and images and generating insights via AI models. These insights will help improve understanding of disease progression and outcomes and support the development of new algorithms for best-in-class management.
Streamlining clinical practice workflows
On the clinical front, the Discovery® platform will be piloted as a centralized, single-system platform for comprehensive Electronic Health Record (EHR) and image management within the Gutblick clinical network (comprising >10 locations in Switzerland). The goal is to centralize medical data collection and automate workflows into one streamlined system, unifying the disparate and multiple software systems currently in use. Clinical information from patient visits will be collected via Discovery®, serving as the main data entry point for imaging for the clinic. As a result, clinicians will be able to effectively search for patients based on target-based anatomical AI-based biomarkers on images to identify those who will benefit the most from PBM (photobiomodulation) therapy using the Valeda (Lumithera inc.), significantly improving the efficiency and effectiveness of patient care.
RetinAI Discovery will also support ongoing patient management through progression analytics, enabling a deeper understanding of patient diseases over time, and the impact of treatment, supporting patient-physician interactions and engagement. This patient-centric care model helps to foster strong clinician-patient relationships and aligns with the goals of becoming a clinical center of excellence, implementing technology to improve patient outcomes.
Carlos Ciller, CEO and co-founder of RetinAI, said: “By utilizing our Discovery® platform in this project, we aim to revolutionize iAMD management and Geographic Atrophy understanding through AI-driven insights and large-scale real-world analysis, paving the way for personalized, top-tier eye care.”
(Press release)
Please login or sign up to comment.
Commenting guidelines